Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Nov;75(11):5434-42.
doi: 10.1128/IAI.00411-07. Epub 2007 Jul 30.

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis

Affiliations

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis

Vincent E Weynants et al. Infect Immun. 2007 Nov.

Abstract

Neisseria meningitidis serogroup B is a major cause of bacterial meningitis in younger populations. The available vaccines are based on outer membrane vesicles obtained from wild-type strains. In children less than 2 years old they confer protection only against strains expressing homologous PorA, a major, variable outer membrane protein (OMP). We genetically modified a strain in order to eliminate PorA and to overproduce one or several minor and conserved OMPs. Using a mouse model mimicking children's PorA-specific bactericidal activity, it was demonstrated that overproduction of more than one minor OMP is required to elicit antibodies able to induce complement-mediated killing of strains expressing heterologous PorA. It is concluded that a critical density of bactericidal antibodies needs to be reached at the surface of meningococci to induce complement-mediated killing. With minor OMPs, this threshold is reached when more than one antigen is targeted, and this allows cross-protection.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Schematic representation of the pCMK vectors used to deliver genes, operons, and/or expression cassettes in the genome of N. meningitidis. MCS, multiple cloning site.
FIG. 2.
FIG. 2.
Overproduction of Omp85, Hsf, TbpA, and NspA. (A) Impact on the content of proteins in MenB OMVs. OMVs purified from different N. meningitidis strains were separated by SDS-PAGE and stained with Coomassie brilliant blue. The strains used are wild-type strain H44/76 (lanes 1 and 7), a galE porA mutant derivative of H44/76 (lane 2), and galE porA mutants overexpressing Omp85 (lane 3), Hsf (lane 4), TbpA (lane 5), Hsf and TbpA simultaneously (lane 6), or NspA (lane 8). In lane 8, bands corresponding to denatured and nondenatured NspA are present. (B) Impact on the induction of antibodies against minor OMPs in mice immunized with OMVs purified from either overproducing strains or control strains or in mice immunized with adjuvant alone (AS04) (20 mice per group). Overproduction was achieved by either the promoter replacement (PR) or gene delivery (GD) strategy. ELISA titers are expressed as the reciprocal dilutions of pooled sera required to obtain an OD490 of 0.5, using purified recombinant TbpA, Hsf, NspA, or Omp85.
FIG. 3.
FIG. 3.
Bactericidal activity against N. meningitidis strains of serum antibodies from mice immunized with OMV vaccines. Sera from 20 mice (see Table 4) were pooled, and two to four pools were combined. Bactericidal assays with (A) H44/76 and (B) Cu385 were performed using pooled sera from mice immunized with OMVs from either TbpA-, Hsf-, or Tbp/Hsf-overproducing strains or with a 1:1 (vol/vol) mixture of serum pools from mice immunized with OMVs from TbpA- and Hsf-overproducing strains. Bactericidal activity is expressed as the reciprocal antibody titer. (C) Bactericidal assays with strain M97-250687 were performed using pooled sera from mice immunized with OMVs from either Omp85-, NspA-, or TbpA/Hsf-overproducing strains or a combination thereof. The data are the means of three different mixing experiments performed using the same serum samples and are expressed as the reciprocal bactericidal titers.
FIG. 4.
FIG. 4.
Schematic representation of the impact of the antigen density on the bactericidal activity of antibodies on the surface of coccal MenB strains. A defined density is required to induce significant bactericidal antibody killing mediated by complement. This threshold density is reached when at least two minor OMPs (Ag 1 and Ag 2) are targeted by antibodies. For an efficacious OMV vaccine, at least two minor OMPs must be overproduced, resulting in vaccine-induced bactericidal antibody killing. Ag, antigen; Abs, antibodies; SBA, serum bactericidal activity. The first step of the classical pathway for activation of the complement cascade is binding of the C1q factor to antibodies, leading to the formation of the membrane attack complex.

Similar articles

Cited by

References

    1. Ala'Aldeen, D. A. A., P. Stevenson, E. Griffiths, A. R. Gorringe, L. I. Irons, A. Robinson, S. Hyde, and S. P. Borriello. 1994. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design. Infect. Immun. 62:2984-2990. - PMC - PubMed
    1. Bernadac, A., M. Gavioli, J. C. Lazzaroni, S. Raina, and R. Lloubès. 1998. Escherichia coli tol-pal mutants form outer membrane vesicles. J. Bacteriol. 180:4872-4878. - PMC - PubMed
    1. Bos, M. P., and J. Tommassen. 2004. Biogenesis of the Gram-negative bacterial outer membrane. Curr. Opin. Microbiol. 7:610-616. - PubMed
    1. Comanducci, M., S. Bambini, B. Brunelli, J. Adu-Bobie, B. Aricò, B. Capecchi, M. M. Giuliani, V. Masignani, L. Santini, S. Savino, D. M. Granoff, D. A. Caugant, M. Pizza, R. Rappuoli, and M. Mora. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195:1445-1454. - PMC - PubMed
    1. Connolly, M., and N. Noah on behalf of the European Meningitis Surveillance Group. 1999. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. Epidemiol. Infect. 122:41-49. - PMC - PubMed

Publication types